Literature DB >> 21811775

Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.

Kshatresh Dutta Dubey1, Rajendra Prasad Ojha.   

Abstract

Abl kinase plays a decisive role in the mechanism of the most fatal human pathogen chronic mylogenous leukemia (CML). Here, we have carried out a comprehensive study about the conformational flexibility, role of salt bridge and the protein- ligand interaction for this kinase with its well-known inhibitor, Imatinib. We have performed molecular dynamics simulations for conformational behavior, investigated the salt bridges and calculated the binding free energy of Imatinib with MM-PB/SA method for Abl kinase complex. We also explored the role of salt-bridge in the kinase complex and its effect on binding activity of inhibitors. Furthermore, to investigate the importance of those residues which form salt bridges, we mutated them by Alanine with the help of Alanine scanning program. We noticed significant variations in total free energy of Imatinib in all possible mutations. The binding free energy of ligand for kinase receptor was analyzed by molecular mechanics Poission Boltzmann surface area (MM-PB/SA) method. These results suggest that conserved glutamic acid and lysine are necessary for stability of complex.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811775     DOI: 10.1007/s00894-011-1199-9

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf.

Authors:  Holger Gohlke; David A Case
Journal:  J Comput Chem       Date:  2004-01-30       Impact factor: 3.376

3.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

4.  The molecular perspective: c-Abl tyrosine kinase.

Authors:  David S Goodsell
Journal:  Oncologist       Date:  2005-10

5.  Unraveling the importance of protein-protein interaction: application of a computational alanine-scanning mutagenesis to the study of the IgG1 streptococcal protein G (C2 fragment) complex.

Authors:  Irina S Moreira; Pedro A Fernandes; Maria J Ramos
Journal:  J Phys Chem B       Date:  2006-06-08       Impact factor: 2.991

6.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

7.  c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

Authors:  Bhushan Nagar
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

8.  Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Authors:  Ralf Buettner; Tania Mesa; Adina Vultur; Frank Lee; Richard Jove
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

9.  Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Authors:  Bhushan Nagar; Oliver Hantschel; Matthew A Young; Klaus Scheffzek; Darren Veach; William Bornmann; Bayard Clarkson; Giulio Superti-Furga; John Kuriyan
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

View more
  1 in total

1.  Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.

Authors:  Vivek Kumar Singh; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2017-07-01       Impact factor: 1.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.